1. Introduction {#sec1-ijms-17-00216}
===============

Traumatic brain injury (TBI) is not only a primary injury, caused by external physical forces, but also a secondary injury caused by a series of biological processes. These include metabolic, cellular, and other molecular events that eventually lead to the death of brain cells, tissue and nerve damage, and atrophy \[[@B1-ijms-17-00216]\]. Due to the importance of the brain, damage to this organ usually causes particularly complex symptoms relative to other injuries. For example, if the blood--brain barrier (BBB), a selectively permeable barrier to the transport of crucial elements for the brain, is damaged by an external force, several complications can occur due to disrupted homeostasis of the brain \[[@B2-ijms-17-00216]\]. In order to take all aspects of the consequences of a TBI into account, and as knowledge on TBIs develops, treatment has become extremely complex and increasingly difficult \[[@B3-ijms-17-00216]\]. Immediately after a TBI, primary injuries resulting from the initial trauma cause rupture of blood vessels, hemorrhaging, structural deformation of tissues, and massive death of neurons and other cells at injured sites \[[@B4-ijms-17-00216]\]. Treatment of the primary injuries of a TBI is similar to those of other traumas. As a result of advances in the treatment of emergency traumas, secondary injuries have become the main cause of morbidity and mortality in TBI patients. Several studies have therefore concentrated on the treatment of secondary injuries resulting from TBIs in an effort to reduce the extent and effect of these injuries.

Secondary injuries are influenced by the vascular perturbations, cerebral metabolic dysfunction, and inadequate cerebral oxygenation related to primary injuries \[[@B5-ijms-17-00216]\]. Vascular perturbations can affect the permeability of the BBB, pinocytotic activity of endothelial cells, and the redistribution of ions and neurotransmitters \[[@B6-ijms-17-00216],[@B7-ijms-17-00216]\]. Increased permeability of the BBB leads to edema and subsequent brain swelling, and can increase the risk of brain infections \[[@B8-ijms-17-00216]\]. Intracellular accumulation of potassium and calcium ions can affect the functioning of neurons in information transduction and of mitochondria in metabolism \[[@B9-ijms-17-00216]\]. Elevated glutamate can be observed as early as 5 min after experimental trauma, which may cause excitotoxicity after a TBI \[[@B10-ijms-17-00216]\] and can also affect mitochondrial functioning through oxidative stress \[[@B6-ijms-17-00216]\]. Increased oxidative stress following a TBI is directly related to the pathogenesis of TBIs. Several oxidative markers, including reduced glutathione (GSH), the GSH/oxidized glutathione (GSSG) ratio, glutathione peroxidase (GPx), glutathione reductase (GR), glutathione-*S*-transferase (GST), glucose-6-phosphate dehydrogenase (G-6PD), superoxide dismutase (SOD), and catalase (CAT) are observed after a TBI. Hence, development of antioxidant strategies is of primary interest in ongoing efforts to optimize brain injury treatment \[[@B11-ijms-17-00216]\]. Recently, inflammation was also recognized as a critical element in recovering from a TBI provided that TBI treatment is an option \[[@B12-ijms-17-00216]\]. Inflammation is a general response to external insults and is also modulated by oxidative stress, mitochondrion-mediated metabolism, and cellular states \[[@B5-ijms-17-00216]\]. An interwoven network of a wide variety of functions complicates TBIs and impedes the development of efficient treatments. Therefore, a systematic perspective of the evolution of a TBI is needed to provide a global view of molecular interactions.

In this study, we used a systems biology approach to elucidate protein--protein interactions (PPIs) very soon (4 h) and longer (8, 24, and 72 h) after a TBI \[[@B13-ijms-17-00216]\]. A systems biology approach can provide a systematic view on the interwoven network of functions and interactions between the proteins involved in these complex networks, which are regarded as systems with sub-units (e.g., proteins) connected as a whole. Many PPIs can form PPI networks (PPINs), in which proteins are nodes and their interactions are the edges of the network. We also used a mathematical model with the microarray data to generate quantitative descriptions of the molecular interactions. By comparing injured and control networks, we were able to select some specific interactions and proteins as potential therapeutic or monitoring targets, according to their differential interactions. Connections between these targets and the physiological phenomena of a TBI provide insights into early interventions for TBIs.

2. Results and Discussion {#sec2-ijms-17-00216}
=========================

We built the network biomarkers for the four time points post-TBI. We then used the commercial pathway analysis software MetaCore™ and the free network ontology analysis (NOA) web server to do a functional pathway analysis to reveal the underlying molecular mechanisms of TBI. The main results of this research are the network biomarkers generated by our model, *i.e.*, the proteins with the highest TBI relevance values (TRVs), and the network structure. However, MetaCore™ and NOA enabled us to add deeper medical and biology significance to our results and make them useful for identifying novel strategies for therapy or recovery processes. The powerful MetaCore™ software uses data mining and statistical methods to select valuable information from the biological and medical literature. It provides a more general perspective and enhanced interpretation of our research. The original results from our primary analysis thus form the core findings of this study, and the additional results generated by MetaCore™ and NOA can be viewed as [supplementary information](#app1-ijms-17-00216){ref-type="app"} that is of wider benefit.

2.1. Evolution of Network Biomarkers at the Four Post-Traumatic Brain Injury (TBI) Time Points {#sec2dot1-ijms-17-00216}
----------------------------------------------------------------------------------------------

We built a Differential PPIN (DPPIN) for each of the four post-TBI time points (4, 8, 24, and 72 h) ([Figure 1](#ijms-17-00216-f001){ref-type="fig"}) and calculated the TRV of each protein in the four networks ([Table 1](#ijms-17-00216-t001){ref-type="table"}). The network diagrams ([Figure 1](#ijms-17-00216-f001){ref-type="fig"}) contain more information than just the TRVs, such as that encoded by the edges and nodes. Node size represents the TRV of each protein, and edge width the interaction ability between the two proteins. Red and blue edges respectively indicate positive and negative values of *d~ij~* in Equation (7). We identified statistically significant network marker proteins for the four post-TBI stages by screening the TRV *p*-values. As in our previous study on stroke, we wanted to reveal the repair mechanisms that operate at these four post-TBI time points. After fold change screening (FC (Fold Change) \> 1.5), we identified 27, 50, 48, and 59 significant proteins at 4, 8, 24, and 72 h post-TBI, respectively. We only list the top 20 for each time point in [Table 1](#ijms-17-00216-t001){ref-type="table"}, but provide the full lists in a [supplementary table](#app1-ijms-17-00216){ref-type="app"}. Their corresponding TRVs were in the ranges 4.5--64.5, 4.9--17, 5.3--30.4, and 5.1--34.2, respectively. We used these significant proteins and their PPIs to construct network markers for the four post-TBI time points. The protein relevance values for TBI were much smaller than those we calculated for carcinogenesis in our previous study on cancer \[[@B9-ijms-17-00216],[@B10-ijms-17-00216]\], and the cancer networks were much more complex than the TBI networks. However, the TBI values and network structures were similar to those we identified for stroke. We do not discuss the UBC (Ubiquitin C), protein in this paper because it is a complex issue. *UBC* is a housekeeping gene for many different diseases, such as cancers, stroke, and TBI. Recent findings also demonstrate that Ubiquitin Carboxyl-Terminal Esterase L1 (Ubiquitin Thiolesterase, UCHL1) is a promising biomarker that physically interacts with UBC \[[@B14-ijms-17-00216],[@B15-ijms-17-00216]\]. Our demonstration of UBC's role in the first 72 h after TBI supports the significance of UCHL1 in TBI.

ijms-17-00216-t001_Table 1

###### 

The 20 proteins with the highest TBI relevance values (TRVs) at four time points post-TBI (traumatic brain injury). AvgExp: average expression; Log~2~ FC: log~2~ fold change. This table was generated using the Matlab program developed by our team according to the algorithms described in [Section 3.3](#sec3dot3-ijms-17-00216){ref-type="sec"} and [Supplementary Materials](#app1-ijms-17-00216){ref-type="app"}.

  Protein    TRV     *p*-Value   TBI_AvgExp   Normal_AvgExp   Log~2~ FC
  ---------- ------- ----------- ------------ --------------- -----------
  **4 h**                                                     
  UBC        64.77   \<10^−9^    9545         20,349          −1.09
  HSP90AA1   12.45   0.000167    11,942       22,341          −0.9
  ITGA4      11.92   0.000167    172          280             −0.7
  SUMO1      10.22   0.000167    8999         9258            −0.04
  UBD        9.73    0.000333    126          209             −0.73
  ELAVL1     8.33    0.000667    1549         1785            −0.2
  APP        8.29    0.000667    9608         19,299          −1.01
  NEDD8      8.1     0.000667    4903         5672            −0.21
  PARK2      7.45    0.001833    47           167             −1.83
  EZH2       7.42    0.002       633          362             0.8
  CDKN1A     6.63    0.0045      3046         1920            0.67
  ACTB       6.53    0.005       15,663       26,523          −0.76
  NFATC1     6.53    0.005167    273          77              1.84
  NEDD4      6.22    0.006833    4030         4698            −0.22
  YWHAB      5.81    0.011333    2014         3474            −0.79
  SUMO3      5.77    0.012333    16,117       13,002          0.31
  NR4A1      5.75    0.0125      8539         3969            1.11
  BRCA1      5.46    0.016667    82           216             −1.4
  PRKG2      5.43    0.017667    29           60              −1.06
  LMNA       5.25    0.021333    10,185       5878            0.79
  **8 h**                                                     
  ELAVL1     16.97   0.000868    1609         1082            0.57
  MYC        13.35   0.001157    356          96              1.9
  TRIM27     12.28   0.00135     3114         2773            0.17
  RELA       11.34   0.001446    6282         3408            0.88
  MDM2       10.9    0.001543    2615         2317            0.17
  NXF1       10.48   0.001543    1086         1240            −0.19
  SRPK2      10.4    0.001639    1183         1232            −0.06
  ITGA4      10.26   0.001639    138          231             −0.74
  SUMO1      9.35    0.002314    9180         10,837          −0.24
  CDKN1A     8.92    0.002893    3417         661             2.37
  NEDD8      8.43    0.003857    4659         5525            −0.25
  AR         8.35    0.003857    824          1585            −0.94
  HSPA1A     7.5     0.005593    5663         2112            1.42
  PARK2      7.34    0.006268    28           51              −0.87
  CUL1       7.22    0.006847    4406         4936            −0.16
  PPARG      7.17    0.007329    169          126             0.42
  UBC        6.93    0.0081      26,887       29,005          −0.11
  TDP2       6.69    0.00974     719          1230            −0.78
  BMI1       6.58    0.010511    2465         3576            −0.54
  NFKB1      6.49    0.011765    1896         1398            0.44
  **24 h**                                                    
  CDK2       30.4    0.000563    612          302             1.02
  FN1        25.07   0.000805    2652         1701            0.64
  EGFR       20.02   0.001689    315          197             0.68
  RHOA       17.25   0.002816    4082         4140            −0.02
  HDAC5      16.31   0.003057    4914         7484            −0.61
  UBD        13.24   0.004023    97           219             −1.17
  MAP3K1     12.48   0.004586    876          364             1.27
  MSN        12.27   0.004666    4631         1331            1.8
  BAG3       12.13   0.004747    1206         419             1.52
  SUMO1      12      0.004747    9074         10,206          −0.17
  CDKN1A     11.59   0.004988    4037         740             2.45
  STUB1      10.71   0.005632    6156         5743            0.1
  LYN        10.59   0.006034    350          312             0.17
  APOA1      10.52   0.006195    102          63              0.71
  UBC        10.27   0.006436    30,215       27,824          0.12
  ISG15      10.26   0.006436    1137         469             1.28
  MDFI       9.46    0.007723    659          547             0.27
  SHC1       9.31    0.008045    788          441             0.84
  GRB2       8.91    0.008286    3458         3862            −0.16
  MYC        8.41    0.00901     251          120             1.06
  **72 h**                                                    
  APP        34.02   \<10^−9^    31,743       38,874          −0.29
  ELAVL1     31.92   \<10^−9^    1937         1169            0.73
  FN1        18.2    0.000309    3441         1562            1.14
  PIK3R2     14.17   0.000386    1495         1625            −0.12
  CDK2       13.29   0.000464    529          383             0.47
  EGFR       12.62   0.000464    325          384             −0.24
  VCAM1      12.3    0.000541    1691         994             0.77
  ISG15      11.52   0.000696    1651         628             1.4
  UBC        11.33   0.00085     31,436       28,733          0.13
  CAV1       10.69   0.001005    2024         802             1.34
  TRAF2      9.53    0.001468    1479         1636            −0.15
  BAG3       8.94    0.002473    1205         506             1.25
  SUMO1      8.94    0.002473    7368         9430            −0.36
  NFKB1      8.7     0.002782    2636         1476            0.84
  FBXO6      8.6     0.003014    5920         4444            0.41
  TERF2      8.52    0.003091    878          1464            −0.74
  HNRNPU     8.43    0.003246    150          291             −0.95
  GNB2L1     8.26    0.003632    17,568       10,465          0.75
  SKIL       7.99    0.004405    149          43              1.79
  AURKA      7.89    0.004637    518          175             1.56

We also identified four significant proteins of core network biomarkers (intersections) for the four post-TBI time points: UBC, SUMO1, CDKN1A, and MYC ([Table 2](#ijms-17-00216-t002){ref-type="table"}). Core and specific network biomarkers are important when discussing evolutionary processes. The discovery of these significant proteins, which are consistent throughout the four post-TBI time points, is especially interesting as Natale *et al.* \[[@B16-ijms-17-00216]\] show MYC was the only one of these proteins identified as common to the different TBI models using controlled cortical impact (CCI) and fluid percussion injury (FPI). To comprehensively discuss the evolutionary behavior of TBI, we also summarized the core network (intersections) of each adjacent time point, *i.e.*, 4--8, 8--24, and 24--72 h.

###### 

The constructed traumatic brain injury (TBI) differential protein--protein interaction networks (PPINs; DPPINs) for four time points post-TBI. These figures include edge and node information. The DPPIN is the difference between the TBI PPIN (TPPIN) and non-TBI PPIN (NPPIN). The size of nodes depends on the TBI relevance value (TRV). The proteins with the highest TRVs are defined as the network markers. These figures were created using Cytoscape. (**a**) 4 h; (**b**) 8 h; (**c**) 24 h; (**d**) 72 h. Blue edge means the difference in interaction activity ≤ mean − STD; Red edge means the difference in the interaction activity ≥ mean + STD; Yellow node means the protein with significant CRV.
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###### 

The four significant proteins of core network biomarkers (intersections) for the four post-TBI time points. AvgExp: average expression; Log~2~ FC: log~2~ fold change; Time point: number of hours post-TBI. This table was generated by the Matlab program developed by our team according to the algorithms described in [Section 3.3](#sec3dot3-ijms-17-00216){ref-type="sec"} and [Supplementary Materials](#app1-ijms-17-00216){ref-type="app"}.

  Gene       Time Point (h)   CRV_Value   *p*-Value   Case_AvgExp   Control_AvgExp   Log~2~ FC
  ---------- ---------------- ----------- ----------- ------------- ---------------- -----------
  *UBC*      4                64.77       \<10^−9^    9545          20,349           −1.09
  *UBC*      8                6.93        0.0081      26,887        29,005           −0.11
  *UBC*      24               10.27       0.006436    30,215        27,824           0.12
  *UBC*      72               11.33       0.00085     31,436        28,733           0.13
  *SUMO1*    4                10.22       0.000167    8999          9258             −0.04
  *SUMO1*    8                9.35        0.002314    9180          10,837           −0.24
  *SUMO1*    24               12          0.004747    9074          10,206           −0.17
  *SUMO1*    72               8.94        0.002473    7368          9430             −0.36
  *CDKN1A*   4                6.63        0.0045      3046          1920             0.67
  *CDKN1A*   8                8.92        0.002893    3417          661              2.37
  *CDKN1A*   24               11.59       0.004988    4037          740              2.45
  *CDKN1A*   72               6.68        0.010974    2257          757              1.58
  *MYC*      4                4.84        0.035667    281           144              0.96
  *MYC*      8                13.35       0.001157    356           96               1.9
  *MYC*      24               8.41        0.00901     251           120              1.06
  *MYC*      72               5.93        0.022411    268           63               2.08

Of the biomarkers identified in our analysis, UBC has also been identified in other systems biology reviews of TBI datasets. As Feala \[[@B17-ijms-17-00216]\] mentions, "Animal experiments do not always reproduce the same results across studies. This is primarily because of variations in animal species, injury type and severity, time course of collection, and sampled tissue". For example, MAPT (Microtubule Associated Protein Tau), also known as Tau (Tau proteins are proteins that stabilize microtubules), appears to be a promising biomarker, yet it does not appear to increase in mTBI (mild traumatic brain injury) scenarios. The change in genetic profiles across different time points was especially problematic for us because a practical biomarker should ideally be present and examinable at different time points after the injury. Of the four proteins common among the different time points, only UBC was mentioned in Feala's article \[[@B17-ijms-17-00216]\]. We feel that other proteins that are persistent throughout the course of sampling should also receive additional attention.

The unique genetic profile for UBC, SUMO1, and CDKN1A at the four time points for CCI suggests the need to further assess current biological modeling designs. We have previously found that even the sham control groups require more precise treatment in CCI experimentation \[[@B17-ijms-17-00216]\] and have proposed that unicortical drilling should be performed on the control group. Since improved biological modeling requires additional funding and repeating previous experiments, we have used a systems biology approach to re-analyze the controversial penumbra region. Given that the penumbra region contains salvageable brain tissue and that it lies between the heavily-injured region and the nearly-normal region, we feel that appropriate analysis of this region should disclose valuable information and targets for treatment.

Our analyses revealed significant information regarding the recovery and damage processes in the post-TBI stages. This information provides clues for selecting novel drug targets for therapeutic and recovery processes. Because of article length restrictions, we present these results in a [supplementary table](#app1-ijms-17-00216){ref-type="app"}.

2.2. Network Structure Interpretation of the Four Post-TBI Time Points {#sec2dot2-ijms-17-00216}
----------------------------------------------------------------------

[Figure 1](#ijms-17-00216-f001){ref-type="fig"} and [Table 1](#ijms-17-00216-t001){ref-type="table"} show the difference between the network structures of the four time points. At 4 h post-TBI, the UBC node dominated the network (TRV = 64.8), while the TRVs of the other nodes were all \<15. We discuss the next two most important proteins, heat shock protein HSP90AA1 (Heat shock protein 90) and ITGA4 (integrin α-4 precursor gene) (TRV = 12.4 and 11.9, respectively), below. At 8 h, there were no TRVs greater than 20. However, ELAVL1 (embryonic lethal abnormal vision-like protein 1) (TRV = 17.0) appeared to be a significant protein of neuron-related diseases. At 24 h, CDK2 (cyclin-dependent kinase-2), FN1, and epithelial growth factor receptor (EGFR) (TRV = 30.4, 25, and 20, respectively) dominated the network. We discuss these significant nodes below. Finally, at 72 h, APP (amyloid precursors protein) and ELAVL1 (TRV = 34 and 31.9, respectively) dominated the network. The color and width of the edges in [Figure 1](#ijms-17-00216-f001){ref-type="fig"} reveal some information about the regulatory mechanisms of the proteins, but the model we used in this research focused on PPIs, not genetic regulatory networks (GRNs). We think that the significant nodes we identified are more like "hubs" than drivers. Our team has also developed GRN models \[[@B18-ijms-17-00216]\], but due to limited data types it was not appropriate to apply a GRN model to this dataset.

We discuss the five aforementioned proteins here. (i)HSP90AA1: White *et al.* \[[@B19-ijms-17-00216]\] discussed the relationship between gene expression patterns post-TBI and the inflammatory response. They identified the following significant genes: HSP90AA1, ERAP1 (endoplasmic reticulum aminopeptidase 1), PSMB9 (proteasome subunit beta type-9), CBL (calcineurin B-like), BTK (Bruton's tyrosine kinase), RORA (retinoic acid receptor-related orphan receptor alpha), THRA (thyroid hormone receptor alpha), and ITGA5 (Integrin, alpha 5, fibronectin receptor).(ii)*ITGA4* (Integrin, α-4 precursor gene): White *et al.* identified ITGA5, but not ITGA4 \[[@B19-ijms-17-00216]\]. They are in the same family. ITGA4 is always related to inflammation caused by stroke or TBI. Fulmer discussed epilepsy drug effects on these proteins \[[@B20-ijms-17-00216]\].(iii)CDK2: Zhang discussed the relationships between the expression of BAD, CDK2, and STAT3, and brain function after a TBI in rats \[[@B21-ijms-17-00216]\].(iv)FN1: White *et al.* discussed the complex behaviors of FN1, such as its extracellular matrix/cell adhesion (FN1, matrix metalloproteinases (MMPs), and ICAM1) module, its fold changes in a gene interaction hierarchy (GIH) analysis, and others \[[@B19-ijms-17-00216]\].(v)EGFR: This is a well-known cancer oncogene and the vascular EGFR (VEGFR) receptor is always reported in brain injuries \[[@B22-ijms-17-00216]\]. It is a novel clue for us to identify the relationship between EGFR and TBI.

2.3. Comparison with Our Previous Results for Stroke {#sec2dot3-ijms-17-00216}
----------------------------------------------------

We compare our results with our recently conducted work on human stroke \[[@B23-ijms-17-00216]\]. We identified five significant proteins common to both stroke and TBI: UBC, APP, NEDD8, PAN2, and EVAVL1.

APP activates voltage-dependent calcium channels and may induce neuronal apoptosis. Its protein product binds growth factor receptor and plays a role in the regulation of peptidase activator and acetylcholine receptor activities. It is involved in the positive regulation of peptidase activity, locomotor behavior, and axon cargo transport. It also participates in the glypican signaling pathway and Alzheimer disease (AD) pathway \[[@B24-ijms-17-00216],[@B25-ijms-17-00216]\]. It is involved in many cellular behaviors and thus forms one of the key hubs in TBI.

NEDD8 (neural precursor cell expressed) encodes a protein that exhibits ubiquitin protein ligase binding. It is involved in protein neddylation. It participates in the p53 signaling pathway, the neddylation pathway, and the cullin-dependent proteasome degradation pathway. It is also associated with Parkinson's disease \[[@B25-ijms-17-00216],[@B26-ijms-17-00216]\].

There are few reports that PAN2 is directly related to TBI or stroke, so this could be a novel target for therapy. The ELAVL1/Hu family of RBPs (RIM binding proteins) plays a key role in neuroscience. Skliris *et al.* \[[@B27-ijms-17-00216]\] discuss how neuroprotective behavior requires the functions of the RNA-binding protein, HuR, and give a full description of the mechanisms of ELAVL1/HuR. Usually, three members of this family (HuB/HEL-N1/ELAVL2, HuC/ELAVL3, and HuD/ELAVL4) are expressed by neurons, but ELAVL1/HuR is always expressed in both neuronal and non-neuronal tissues. These findings concur with descriptions of the involvement of synaptic dysfunction and cytoarchitectural degradation in stroke \[[@B28-ijms-17-00216]\].

2.4. MetaCore™ Results {#sec2dot4-ijms-17-00216}
----------------------

We used the MetaCore™ Analyze Networks (AN) algorithm to analyze the network biomarkers that were unique to or common to all or some of the networks we identified for the four time points post-TBI ([Table 3](#ijms-17-00216-t003){ref-type="table"}). The detailed algorithm is given in [Supplementary Material S0](#app1-ijms-17-00216){ref-type="app"}, showing that completely different cellular behaviors are operating at the four time points. Briefly, most biomarkers at 4 h post-TBI were related to cell activation and signaling behaviors. In contrast, most at 8 h post-TBI were related to immune response. At 24 h post-TBI, most were related to DNA behavior, whereas in the final 72 h post-TBI stage, most were related to regulation and apoptotic behaviors. The evolution of cellular behavior at these four time points post-TBI is thus clear.

A canonical pathway in MetaCore™ represents a set of consecutive signals, or metabolic transformations, confirmed as a whole by experimental data or by inferred relationships. They are linear sets of carefully defined steps that form a map; in MetaCore™, complete biochemical pathways or signaling cascades in the commonly accepted sense correspond to maps. Over 70,000 pathways are stored in MetaBase™, which are mainly used for network generation and visualized as canonical pathway maps. The AN algorithm creates a large network and divides it into smaller sub-networks that can be separately built. Networks are more interactive than pathway maps and can sometimes be more complex.

ijms-17-00216-t003_Table 3

###### 

Analysis of networks using MetaCore™. The gene content of the uploaded files was used as the input list for generating biological networks using the Analyze Networks (AN) algorithm with default settings. This is a variant of the shortest paths algorithm, with the following main parameters: (1) relative enrichment with the uploaded data and (2) relative saturation of networks with canonical pathways. These networks are built on the fly and are unique to the uploaded data. In this workflow, the networks are prioritized based on the number of fragments of canonical pathways in the network. S: size; T: target; P: pathways; G: gScore.

  No.                                          Processes                                                                                                                                                                                                                                                                                                                                S    T    P    G
  -------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---- ---- ---- -------
  **Common to All Four Networks**                                                                                                                                                                                                                                                                                                                                                                      
  1                                            Viral transcription (97.1%), viral genome expression (97.1%), translational termination (97.1%), cellular protein complex disassembly (97.1%), SRP (signal recognition particle)-dependent cotranslational protein targeting to membrane (97.1%).                                                                                        38   1    0    11.39
  **Common to Two or Three of the Networks**                                                                                                                                                                                                                                                                                                                                                           
  1                                            Positive regulation of nucleobase-containing compound metabolic process (75.5%), positive regulation of biosynthetic process (77.6%), enzyme-linked receptor protein signaling pathway (65.3%), positive regulation of nitrogen compound metabolic process (75.5%), positive regulation of macromolecule biosynthetic process (73.5%).   50   16   0    69.15
  2                                            Positive regulation of response to stimulus (60.4%), regulation of response to stimulus (75.0%), response to organic substance (72.9%), transmembrane receptor protein tyrosine kinase signaling pathway (45.8%), response to hormone stimulus (56.2%).                                                                                  50   14   0    56.71
  3                                            Cell surface receptor signaling pathway (96.0%), signal transduction (96.0%), signaling (96.0%), single organism signaling (96.0%), cell communication (96.0%).                                                                                                                                                                          50   2    30   45.94
  **Unique to the 4 h Post-TBI Network**                                                                                                                                                                                                                                                                                                                                                               
  1                                            Cell activation (54.0%), signal transduction (94.0%), signaling (96.0%), single organism signaling (96.0%), response to wounding (62.0%).                                                                                                                                                                                                50   6    0    43.25
  2                                            G-protein coupled receptor signaling pathway (71.4%), neuropeptide signaling pathway (30.6%), G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger (32.7%), cell surface receptor signaling pathway (75.5%), chemokine-mediated signaling pathway (20.4%).                                        50   5    0    36.02
  3                                            Axis specification (38.0%), canonical Wnt receptor signaling pathway (36.0%), pattern specification process (46.0%), Wnt receptor signaling pathway (38.0%), anterior/posterior pattern specification (36.0%).                                                                                                                           50   4    0    28.78
  **Unique to the 8 h Post-TBI Network**                                                                                                                                                                                                                                                                                                                                                               
  1                                            Response to abiotic stimulus (61.7%), regulation of apoptotic process (63.8%), regulation of programmed cell death (63.8%), positive regulation of cellular process (85.1%), positive regulation of metabolic process (74.5%).                                                                                                           50   9    0    41.50
  2                                            Positive regulation of immune response (43.8%), positive regulation of response to stimulus (58.3%), regulation of response to stress (52.1%), regulation of immune response (47.9%), TRIF (Toll/IL-1 receptor domain-containing adapter inducing interferon-β)-dependent toll-like receptor signaling pathway (27.1%).                  50   8    0    36.87
  3                                            Immune response-activating signal transduction (25.0%), immune response-regulating signaling pathway (25.0%), T cell costimulation (17.5%), lymphocyte costimulation (17.5%), cellular defense response (17.5%).                                                                                                                         50   5    2    25.40
  **Unique to the 24 h Post-TBI Network**                                                                                                                                                                                                                                                                                                                                                              
  1                                            Double-strand break repair via synthesis-dependent strand annealing (100.0%), DNA recombinase assembly (100.0%), DNA excision (100.0%), telomere maintenance via semi-conservative replication (100.0%), nucleotide-excision repair, DNA gap filling (100.0%).                                                                           4    2    0    33.30
  2                                            Lipoprotein metabolic process (46.2%), protein-lipid complex assembly (34.6%), plasma lipoprotein particle assembly (34.6%), lipid transport (50.0%), lipid localization (50.0%).                                                                                                                                                        49   6    0    30.34
  3                                            Immune response (56.5%), immune system process (67.4%), positive regulation of response to stimulus (58.7%), activation of immune response (39.1%), positive regulation of immune system process (47.8%).                                                                                                                                50   6    0    28.11
  **Unique to the 72 h Post-TBI Network**                                                                                                                                                                                                                                                                                                                                                              
  1                                            Positive regulation of biological process (98.0%), positive regulation of cellular process (90.0%), enzyme linked receptor protein signaling pathway (56.0%), regulation of immune system process (60.0%), regulation of response to stimulus (76.0%).                                                                                   50   13   0    65.57
  2                                            Positive regulation of apoptotic process (58.0%), positive regulation of programmed cell death (58.0%), positive regulation of cell death (58.0%), positive regulation of biological process (90.0%), regulation of apoptotic process (66.0%).                                                                                           50   11   0    55.45
  3                                            Enzyme linked receptor protein signaling pathway (63.8%), membrane protein intracellular domain proteolysis (25.5%), nerve growth factor receptor signaling pathway (40.4%), membrane protein proteolysis (25.5%), transmembrane receptor protein tyrosine kinase signaling pathway (46.8%).                                             50   10   0    50.91

### 2.4.1. Statistical Interpretation of MetaCore™ {#sec2dot4dot1-ijms-17-00216}

[Figure 2](#ijms-17-00216-f002){ref-type="fig"}d and [Figure 4](#ijms-17-00216-f004){ref-type="fig"}d are statistical interpretation of MetaCore™. The comparison tool, after the user has set the various options, generates a number of intersecting sets. The number of sets generated depends on the number of active experiments (in this case, time points post-TBI under consideration, *i.e.*, four). They overlap where they have network objects in common. The different elements of the resulting Venn diagram comprise of the following: (1) a "common" area in the middle, including the network objects found in all the experiments (in this case, at all four time points); (2) an area "unique" to each experiment, consisting of objects unique to that experiment; and (3) one or more sets of objects common to two or more experiments, but not all (MetaCore™).

### 2.4.2. Three Statistical Results for the Four Time Points Post-TBI {#sec2dot4dot2-ijms-17-00216}

[Figure 2](#ijms-17-00216-f002){ref-type="fig"}a gives the top 10 pathway maps. [Figure 2](#ijms-17-00216-f002){ref-type="fig"}b gives the top 10 process networks. They are highly related to the cell cycle, DNA damage, and signal transduction. These pathways and process networks may provide clues for new uses of conventional drugs. From the literature review, we also found that it was important to pay attention to the relationship between the cell cycle and TBI \[[@B29-ijms-17-00216]\]. Simone *et al.* discuss the fact that cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. This article has been cited more than 250 times, and therefore the discussion of the relationship of the cell cycle and TBI is very important. [Figure 2](#ijms-17-00216-f002){ref-type="fig"}c gives results for related diseases. While one can make comparisons of common hidden embryological and molecular mechanisms of these diseases, the correlation and embryological relationship amongst TBI and these diseases, however, would require additional investigation and validation.

###### 

Results of the MetaCore™ analysis for all four time points post-TBI (4 h, 8 h, 24 h, and 72 h). All results are sorted according to those most strongly represented in the "common" set. (**a**) Pathway maps. Canonical pathway maps represent a set of signaling and metabolic maps that comprehensively cover human biological functioning. All maps are created by Thomson Reuters scientists using a high quality manual curation process based on published peer reviewed literature. Experimental data are visualized on the maps as blue (for downregulation) and red (upregulation) histograms. The height of the histogram corresponds to the relative expression value for a particular gene/protein; (**b**) Process networks. The content of these cellular and molecular processes is defined and annotated by Thomson Reuters scientists. Each process represents a pre-set network of protein interactions characteristic of that process; (**c**) Related diseases (determined based on biomarkers). Related disease folders are organized into a hierarchical tree. Gene content may vary greatly between such complex diseases as cancers and some Mendelian diseases. Also, coverage of different diseases in literature is skewed. These two factors may affect *p-*value prioritization for diseases; (**d**) Figure legend giving the meanings of the colors and statistical interpretation of the above three figures. These figures were generated by MetaCore™.
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### 2.4.3. The Highest-Scoring Pathway Map of Post-TBI-Related Biomarker Genes at the Four Time Points {#sec2dot4dot3-ijms-17-00216}

The highest-scoring pathway map we identified using MetaCore for the four time points was DNA damage ATM (Ataxia-telangiectasia mutated )/ATR (Ataxia-telangiectasia and Rad3-related) regulation of G1/S checkpoint ([Figure 3](#ijms-17-00216-f003){ref-type="fig"}a). The ATM-Chk2 (ataxia telangiectasia mutated--checkpoint kinase 2) and ATR-Chk1 pathways are two distinct kinase signaling cascades that primarily coordinate cellular responses to DNA damage. The DNA damage checkpoints may arrest or delay progression of cell cycles in response to DNA damage. Notably, NF-κB, c-MYC, and P21 were up-regulated at all four time points relative to the time at which the injury occurred. Ubiquitin was down-regulated at both 4 and 8 h and up-regulated at 24 and 72 h. BRCA1 was down-regulated and MDM2 and I-κB were up-regulated at 4 h. PCNA was up-regulated at 24 h and CDK2 was up-regulated at 24 and 72 h. The second highest-scoring map was Cell Cycle ESR1 regulation of G1/S transition, which is also a cell cycle associated pathway ([Figure 3](#ijms-17-00216-f003){ref-type="fig"}b). C-MYC and P21 were up-regulated at all four time points. ATF-2/c-Jun, c-Jun, and c-Jun/c-Fos were up-regulated at both 8 and 24 h. SP1, Cullin 1, and Cul1/Rbx1 E3 ligase were down-regulated at 8 h. CDK2 was up-regulated at both 24 and 72 h. These results show that our identified biomarker genes are strongly associated with the cell cycle and may play important roles in post-TBI regulation.

###### 

The two highest-scoring maps for all four time points post-TBI. (**a**) DNA damage ATM/ATR regulation of G1/S checkpoint; (**b**) Cell cycle ESR1 regulation of G1/S transition. These figures were generated by MetaCore™.
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### 2.4.4. Three Statistical Results for the Last Two Time Points Post-TBI {#sec2dot4dot4-ijms-17-00216}

The 10 top-scoring pathway maps ([Figure 4](#ijms-17-00216-f004){ref-type="fig"}a) and process networks ([Figure 4](#ijms-17-00216-f004){ref-type="fig"}c) for the last two time points post-TBI (24 and 72 h) are strongly related to the cell cycle, DNA damage, and signal transduction. The results regarding related diseases ([Figure 4](#ijms-17-00216-f004){ref-type="fig"}c) provide clues about new uses for conventional drugs and facilitate comparisons of the hidden molecular mechanisms common to some of these diseases.

### 2.4.5. The Highest-Scoring Pathway Map of Post-TBI-Related Biomarker Genes at 24 and 72 h {#sec2dot4dot5-ijms-17-00216}

The highest-scoring pathway map at 24 and 72 h, according to the MetaCore™ analysis, is Cell Cycle Role of SCF Complex (Skp, Cullin, F-box containing complex) in Cell Cycle Regulation ([Figure 5](#ijms-17-00216-f005){ref-type="fig"}a). The S-phase kinase-associated protein (SKP1)/Cullin/F-box (SCF) complex is one of the E3-ubiquitin ligases, and plays a critical role in the cell cycle. Surprisingly, ubiquitin was down-regulated at 4 and 8 h, but up-regulated at 24 and 72 h. CDK1 and CDK2 were up-regulated at 24 and 72 h, and P21 was up-regulated at all four time points. Another pathway related to the cell cycle, influence of Ras and Rho proteins on G1/S transition, was also identified as strongly associated with biomarker genes at 24 and 72 h ([Figure 5](#ijms-17-00216-f005){ref-type="fig"}b). These genes, such as *P21*, *CDK2*, *ERK1*/2, *MDM2*, *STAT3*, *RhoA*, *NF*-*κB*, might provide clues for deciphering the regulatory mechanisms of post-TBI processes at different time points.

###### 

Results of the MetaCore™ analysis for the last two time points post-TBI (24 and 72 h). Results are sorted according to those most strongly represented in the "common" set. (**a**) Pathway maps. Canonical pathway maps represent a set of signaling and metabolic maps that comprehensively cover human biological functioning. All maps are created by Thomson Reuters scientists using a high quality manual curation process based on published peer reviewed literature. Experimental data is visualized on the maps as blue (for down-regulation) and red (up-regulation) histograms. The height of the histogram corresponds to the relative expression value for a particular gene/protein; (**b**) Gene ontology (GO) cellular processes. Since most GO processes have no gene/protein content, the "empty terms" are excluded from *p-*value calculations; (**c**) Process networks. The content of these cellular and molecular processes is defined and annotated by Thomson Reuters scientists. Each process represents a pre-set network of protein interactions characteristic for the process; (**d**) Figure legend giving the meanings of the colors and statistical interpretation of the above three figures. These figures were generated by MetaCore™.
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![The highest-scoring and fifth highest-scoring pathway maps for the last two time points post-TBI (24 and 72 h). (**a**) Cell cycle: role of SCF complex in cell cycle regulation; (**b**) Cell cycle: Influence of Ras and Rho proteins on G1/S Transition. These figures were generated by MetaCore™.](ijms-17-00216-g005){#ijms-17-00216-f005}

### 2.4.6. Top-Scoring AN (Analyze Networks Algorithm) Results for the Four Time Points Post-TBI {#sec2dot4dot6-ijms-17-00216}

The AN results for the four time points provide information about canonical pathways, up-regulated and down-regulated genes, and mixed expression genes ([Figure 6](#ijms-17-00216-f006){ref-type="fig"}).

### 2.4.7. Discussion of the Cell Cycle Behavior of TBI {#sec2dot4dot7-ijms-17-00216}

Our results show that the cell cycle is strongly related to brain injury ([Figure 1](#ijms-17-00216-f001){ref-type="fig"}). Wu *et al.* \[[@B30-ijms-17-00216]\] discuss cell cycle activation and cord injury, stating that a traumatic spinal cord injury (SCI) causes a series of events involving initial mechanical damage, secondary injury processes, and eventually results in tissue loss and functional impairment. They also found that the cell cycle is activated following an SCI \[[@B30-ijms-17-00216]\].

2.5. Network Ontology Analysis (NOA) Results {#sec2dot5-ijms-17-00216}
--------------------------------------------

The detailed analytical results of the network ontology analysis (NOA) highlight the evolutionary process at the four time points post-TBI with respect to biological processes, cellular components, and molecular functions ([Table 4](#ijms-17-00216-t004){ref-type="table"}). For example, the most statistically significant biological process at 4 h post-TBI was protein modification by small-protein conjugation, while the top processes at the other three time points were positive regulation of cellular metabolic processes. The top cellular components at the four time points were protein complex, nucleus, intracellular part, and cytoplasm, respectively. The top molecular function at all four time points was protein binding, followed by enzyme binding, promoter binding, receptor signaling protein activity, and identical protein binding, at 4, 8, 24, and 72 h post-TBI, respectively.

###### 

Top-scoring networks for (**a**) 4 h; (**b**) 8 h; (**c**) 24 h; and (**d**) 72 h post-TBI. Scoring was based on the number of pathways. Thick cyan lines indicate fragments of canonical pathways. Up-regulated genes are marked with red circles, and down-regulated with blue circles. A "checkerboard" pattern indicates mixed expression for the gene between files or between multiple tags for the same gene. These figures were generated by MetaCore™.
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2.6. Summary of the Results in [Table 4](#ijms-17-00216-t004){ref-type="table"} {#sec2dot6-ijms-17-00216}
-------------------------------------------------------------------------------

In addition to our original analysis that identified the PPINs and their corresponding network biomarkers, we have generated abundant results using DAVID (The Database for Annotation, Visualization and Integrated Discovery; Available online: <https://david.ncifcrf.gov/home.jsp>), MetaCore™, and NOA. Based on our previous experience with cancer research, we applied the David analysis to the four time points post-TBI and expected it to yield the results of KEGG (Kyoto Encyclopedia of Genes and Genomes; Available online: <http://www.genome.jp/kegg/>). However, we did not find the KEGG database suitable for analyzing TBI (most entries were linked to cancer-related pathways), so we present these results in [Supplementary Material S4](#app1-ijms-17-00216){ref-type="app"} and do not describe them here.

Here, we emphasize the importance of the results of the MetaCore™ and NOA analyses. They can be used as references for medical and basic researchers performing further explorations of the hidden mechanisms of network biomarkers, and will also help these researchers to develop novel strategies for TBI therapy or recovery processes. Our original results can also be used for further analysis using other methods, so we present them here.

ijms-17-00216-t004_Table 4

###### 

Network ontology pathway analysis and gene set enrichment analysis for four time points post-TBI with respect to (1) biological processes; (2) cellular components; and (3) molecular functions. Each of these tables is presented for each of the four time points. R: number of genes in reference set; T: number of genes in test set; G: number of genes annotated by given term in reference set; O: number of genes annotated by given term in test set. This table is produced based on data stored in the network ontology analysis (NOA) web server.

  GO: Term                       *p-*Value        Corrected *p*-Value   R              T    G        O    Term Name
  ------------------------------ ---------------- --------------------- -------------- ---- -------- ---- --------------------------------------------------------------------------------------------------------------------
  **4 h Post-TBI**                                                                                        
  **(1) Biological Processes**                                                                            
  GO:0032446                     1.1 × 10^−8^     1.0 × 10^−5^          14,791         26   168      7    protein modification by small protein conjugation
  GO:0070647                     4.5 × 10^−8^     3.8 × 10^−5^          14,791         26   204      7    protein modification by small protein conjugation or removal
  GO:0043687                     3.7 × 10^−7^     3.1 × 10^−4^          14,791         26   1243     12   post-translational protein modification
  GO:0048518                     5.1 × 10^−7^     4.4 × 10^−4^          14,791         26   2188     15   positive regulation of biological process
  GO:0043067                     8.5 × 10^−7^     7.2 × 10^−4^          14,791         26   850      10   regulation of programmed cell death
  GO:0010941                     9.0 × 10^−7^     7.7 × 10^−4^          14,791         26   856      10   regulation of cell death
  GO:0048522                     1.1 × 10^−6^     9.8 × 10^−4^          14,791         26   1984     14   positive regulation of cellular process
  GO:0042221                     1.3 × 10^−6^     0.0011                14,791         26   1402     12   response to chemical stimulus
  GO:0009314                     1.5 × 10^−6^     0.0013                14,791         26   215      6    response to radiation
  GO:0006464                     2.6 × 10^−6^     0.0022                14,791         26   1490     12   protein modification process
  **(2) Cellular Components**                                                                             
  GO:0043234                     7.1 × 10^−6^     9.3 × 10^−4^          16,768         25   2748     14   protein complex
  GO:0044451                     1.8 × 10^−5^     0.0024                16,768         25   594      7    nucleoplasm part
  GO:0005737                     2.3 × 10^−5^     0.0030                16,768         25   4549     17   cytoplasm
  GO:0017053                     3.4 × 10^−5^     0.0045                16,768         25   43       3    transcriptional repressor complex
  GO:0044428                     4.4 × 10^−5^     0.0057                16,768         25   1932     11   nuclear part
  GO:0016235                     4.4 × 10^−5^     0.0058                16,768         25   7        2    aggresome
  GO:0032991                     6.5 × 10^−5^     0.0085                16,768         25   3312     14   macromolecular complex
  GO:0035098                     7.6 × 10^−5^     0.0100                16,768         25   9        2    ESC/E(Z) complex (Extra Sex Combs/Enhancer of Zeste complex)
  GO:0034708                     7.7 × 10^−5^     0.0100                16,768         25   56       3    methyltransferase complex
  GO:0035097                     7.7 × 10^−5^     0.0100                16,768         25   56       3    histone methyltransferase complex
  **(3) Molecular Functions**                                                                             
  GO:0005515                     7.5 × 10^−7^     1.2 × 10^−4^          15,767         26   8097     25   protein binding
  GO:0019899                     2.9 × 10^−6^     4.8 × 10^−4^          15,767         26   584      8    enzyme binding
  GO:0050815                     1.5 × 10^−5^     0.0025                15,767         26   4        2    phosphoserine binding
  GO:0032403                     4.2 × 10^−5^     0.0069                15,767         26   243      5    protein complex binding
  GO:0016563                     4.9 × 10^−5^     0.0082                15,767         26   419      6    transcription activator activity
  GO:0042802                     8.3 × 10^−5^     0.0139                15,767         26   677      7    identical protein binding
  GO:0016564                     1.7 × 10^−4^     0.0292                15,767         26   329      5    transcription repressor activity
  GO:0045309                     2.7 × 10^−4^     0.0449                15,767         26   15       2    protein phosphorylated amino acid binding
  GO:0004407                     3.0 × 10^−4^     0.0513                15,767         26   16       2    histone deacetylase activity
  GO:0033558                     3.5 × 10^−4^     0.0581                15,767         26   17       2    protein deacetylase activity
  **8 h Post-TBI**                                                                                        
  **(1) Biological Processes**                                                                            
  GO:0031325                     4.7 × 10^−11^    5.9 × 10^−8^          14,791         48   965      19   positive regulation of cellular metabolic process
  GO:0009893                     1.1 × 10^−10^    1.4 × 10^−7^          14,791         48   1015     19   positive regulation of metabolic process
  GO:0048523                     1.9 × 10^−10^    2.4 × 10^−7^          14,791         48   1815     24   negative regulation of cellular process
  GO:0042127                     4.4 × 10^−10^    5.6 × 10^−7^          14,791         48   839      17   regulation of cell proliferation
  GO:0031328                     5.0 × 10^−10^    6.3 × 10^−7^          14,791         48   727      16   positive regulation of cellular biosynthetic process
  GO:0009891                     6.5 × 10^−10^    8.2 × 10^−7^          14,791         48   740      16   positive regulation of biosynthetic process
  GO:0048519                     1.2 × 10^−9^     1.5 × 10^−6^          14,791         48   1983     24   negative regulation of biological process
  GO:0048518                     1.5 × 10^−9^     1.8 × 10^−6^          14,791         48   2188     25   positive regulation of biological process
  GO:0051173                     2.0 × 10^−9^     2.6 × 10^−6^          14,791         48   683      15   positive regulation of nitrogen compound metabolic process
  GO:0031323                     2.2 × 10^−9^     2.8 × 10^−6^          14,791         48   3768     32   regulation of cellular metabolic process
  **(2) Cellular Components**                                                                             
  GO:0005634                     4.9 × 10^−11^    8.3 × 10^−9^          16768          45   5037     35   nucleus
  GO:0044428                     7.5 × 10^−11^    1.2 × 10^−8^          16,768         45   1932     23   nuclear part
  GO:0032991                     1.1 × 10^−7^     1.8 × 10^−5^          16,768         45   3312     25   macromolecular complex
  GO:0005737                     1.8 × 10^−7^     3.0 × 10^−5^          16,768         45   4549     29   cytoplasm
  GO:0043231                     3.3 × 10^−7^     5.6 × 10^−5^          16,768         45   7996     38   intracellular membrane-bounded organelle
  GO:0043227                     3.3 × 10^−7^     5.6 × 10^−5^          16,768         45   7998     38   membrane-bounded organelle
  GO:0005829                     5.5 × 10^−7^     9.2 × 10^−5^          16,768         45   1269     15   cytosol
  GO:0043229                     1.1 × 10^−6^     1.8 × 10^−4^          16,768         45   8759     39   intracellular organelle
  GO:0043226                     1.1 × 10^−6^     1.9 × 10^−4^          16,768         45   8773     39   organelle
  GO:0044424                     1.6 × 10^−6^     2.8 × 10^−4^          16,768         45   11,001   43   intracellular part
  **(3) Molecular Functions**                                                                             
  GO:0005515                     1.2 × 10^−11^    3.1 × 10^−9^          15,767         48   8097     46   protein binding
  GO:0010843                     4.0 × 10^−11^    9.9 × 10^−9^          15,767         48   111      9    promoter binding
  GO:0044212                     5.6 × 10^−11^    1.3 × 10^−8^          15,767         48   115      9    DNA regulatory region binding
  GO:0016563                     4.1 × 10^−7^     1.0 × 10^−4^          15,767         48   419      10   transcription activator activity
  GO:0042802                     5.9 × 10^−7^     1.4 × 10^−4^          15,767         48   677      12   identical protein binding
  GO:0003690                     6.2 × 10^−7^     1.5 × 10^−4^          15,767         48   102      6    double-stranded DNA binding
  GO:0035326                     5.7 × 10^−6^     0.0014                15,767         48   39       4    enhancer binding
  GO:0003705                     5.7 × 10^−6^     0.0014                15,767         48   39       4    RNA polymerase II transcription factor activity, enhancer binding
  GO:0043566                     6.1 × 10^−6^     0.0015                15,767         48   151      6    structure-specific DNA binding
  GO:0032403                     8.1 × 10^−6^     0.0019                15,767         48   243      7    protein complex binding
  **24 h Post-TBI**                                                                                       
  **(1) Biological Processes**                                                                            
  GO:0048522                     4.0 × 10^−10^    4.8 × 10^−7^          14,791         46   1984     24   positive regulation of cellular process
  GO:0048518                     4.5 × 10^−10^    5.4 × 10^−7^          14,791         46   2188     25   positive regulation of biological process
  GO:0009987                     9.8 × 10^−9^     1.1 × 10^−5^          14,791         46   9216     45   cellular process
  GO:0050794                     1.3 × 10^−8^     1.5 × 10^−5^          14,791         46   6896     40   regulation of cellular process
  GO:0031325                     1.4 × 10^−8^     1.7 × 10^−5^          14,791         46   965      16   positive regulation of cellular metabolic process
  GO:0051716                     1.9 × 10^−8^     2.3 × 10^−5^          14,791         46   847      15   cellular response to stimulus
  GO:0048523                     2.1 × 10^−8^     2.5 × 10^−5^          14,791         46   1815     21   negative regulation of cellular process
  GO:0009893                     3.0 × 10^−8^     3.5 × 10^−5^          14,791         46   1015     16   positive regulation of metabolic process
  GO:0044260                     4.7 × 10^−8^     5.6 × 10^−5^          14,791         46   3428     28   cellular macromolecule metabolic process
  GO:0051128                     4.9 × 10^−8^     5.9 × 10^−5^          14,791         46   529      12   regulation of cellular component organization
  **(2) Cellular Components**                                                                             
  GO:0044424                     5.6 × 10^−9^     1.0 × 10^−6^          16,768         45   11,001   45   intracellular part
  GO:0005829                     1.1 × 10^−8^     2.1 × 10^−6^          16,768         45   1269     17   cytosol
  GO:0005737                     1.8 × 10^−7^     3.4 × 10^−5^          16,768         45   4549     29   cytoplasm
  GO:0043234                     4.1 × 10^−7^     7.9 × 10^−5^          16,768         45   2748     22   protein complex
  GO:0005634                     4.2 × 10^−7^     8.0 × 10^−5^          16,768         45   5037     30   nucleus
  GO:0032991                     5.5 × 10^−7^     1.0 × 10^−4^          16,768         45   3312     24   macromolecular complex
  GO:0044428                     4.7 × 10^−6^     9.1 × 10^−4^          16,768         45   1932     17   nuclear part
  GO:0000307                     6.4 × 10^−6^     0.0012                16,768         45   14       3    cyclin-dependent protein kinase holoenzyme complex
  GO:0070435                     7.0 × 10^−6^     0.0013                16,768         45   2        2    Shc-EGFR complex (Src homology 2 domain containing transforming protein-epidermal growth factor receptor complex)
  GO:0043229                     2.6 × 10^−5^     0.0051                16,768         45   8759     37   intracellular organelle
  **(3) Molecular Functions**                                                                             
  GO:0005515                     6.4 × 10^−10^    1.7 × 10^−7^          15,767         46   8097     43   protein binding
  GO:0005057                     4.0 × 10^−7^     1.1 × 10^−4^          15,767         46   162      7    receptor signaling protein activity
  GO:0043560                     5.0 × 10^−6^     0.0013                15,767         46   12       3    insulin receptor substrate binding
  GO:0019899                     5.4 × 10^−6^     0.0015                15,767         46   584      10   enzyme binding
  GO:0032403                     6.0 × 10^−6^     0.0016                15,767         46   243      7    protein complex binding
  GO:0004710                     8.3 × 10^−6^     0.0022                15,767         46   2        2    MAP/ERK kinase kinase activity (mitogen-activated protein kinases/extracellular signal-regulated kinases activity)
  GO:0045309                     1.0 × 10^−5^     0.0028                15,767         46   15       3    protein phosphorylated amino acid binding
  GO:0019900                     2.4 × 10^−5^     0.0067                15,767         46   201      6    kinase binding
  GO:0005488                     3.0 × 10^−5^     0.0083                15,767         46   12,581   46   binding
  GO:0004702                     3.1 × 10^−5^     0.0086                15,767         46   62       4    receptor signaling protein serine/threonine kinase activity
  **72 h Post-TBI**                                                                                       
  **(1) Biological Processes**                                                                            
  GO:0048522                     1.60 × 10^−17^   2.50 × 10^−14^        1.48 × 10^4^   56   1984     35   positive regulation of cellular process
  GO:0048518                     3.80 × 10^−17^   5.60 × 10^−14^        1.48 × 10^4^   56   2188     36   positive regulation of biological process
  GO:0031325                     1.60 × 10^−12^   2.40 × 10^−09^        1.48 × 10^4^   56   965      22   positive regulation of cellular metabolic process
  GO:0009893                     4.50 × 10^−12^   6.70 × 10^−09^        1.48 × 10^4^   56   1015     22   positive regulation of metabolic process
  GO:0010604                     9.20 × 10^−12^   1.30 × 10^−08^        1.48 × 10^4^   56   939      21   positive regulation of macromolecule metabolic process
  GO:0032502                     9.30 × 10^−12^   1.30 × 10^−08^        1.48 × 10^4^   56   3032     35   developmental process
  GO:0048519                     5.20 × 10^−11^   7.70 × 10^−08^        1.48 × 10^4^   56   1983     28   negative regulation of biological process
  GO:0006950                     1.00 × 10^−10^   1.50 × 10^−07^        1.48 × 10^4^   56   1591     25   response to stress
  GO:0042981                     1.00 × 10^−10^   1.50 × 10^−07^        1.48 × 10^4^   56   842      19   regulation of apoptosis
  GO:0010033                     1.20 × 10^−10^   1.80 × 10^−07^        1.48 × 10^4^   56   850      19   response to organic substance
  **(2) Cellular Components**                                                                             
  GO:0005737                     9.2 × 10^−11^    1.9 × 10^−8^          16,768         57   4549     39   cytoplasm
  GO:0043234                     1.8 × 10^−9^     4.0 × 10^−7^          16,768         57   2748     29   protein complex
  GO:0005829                     2.6 × 10^−9^     5.6 × 10^−7^          16,768         57   1269     20   cytosol
  GO:0032991                     6.7 × 10^−9^     1.4 × 10^−6^          16,768         57   3312     31   macromolecular complex
  GO:0044428                     2.4 × 10^−8^     5.2 × 10^−6^          16,768         57   1932     23   nuclear part
  GO:0044424                     1.6 × 10^−7^     3.5 × 10^−5^          16,768         57   11,001   54   intracellular part
  GO:0044446                     2.0 × 10^−7^     4.4 × 10^−5^          16,768         57   5015     36   intracellular organelle part
  GO:0044422                     2.9 × 10^−7^     6.3 × 10^−5^          16,768         57   5082     36   organelle part
  GO:0005634                     9.0 × 10^−7^     1.9 × 10^−4^          16,768         57   5037     35   nucleus
  GO:0070435                     1.1 × 10^−5^     0.0024                16,768         57   2        2    Shc-EGFR complex
  **(3) Molecular Functions**                                                                             
  GO:0005515                     2.8 × 10^−17^    6.5 × 10^−15^         15,767         57   8097     57   protein binding
  GO:0042802                     8.7 × 10^−8^     1.9 × 10^−5^          15,767         57   677      14   identical protein binding
  GO:0019899                     1.1 × 10^−7^     2.6 × 10^−5^          15,767         57   584      13   enzyme binding
  GO:0032403                     2.4 × 10^−6^     5.5 × 10^−4^          15,767         57   243      8    protein complex binding
  GO:0005488                     2.5 × 10^−6^     5.7 × 10^−4^          15,767         57   12,581   57   binding
  GO:0019900                     7.5 × 10^−6^     0.0017                15,767         57   201      7    kinase binding
  GO:0016566                     1.0 × 10^−5^     0.0023                15,767         57   38       4    specific transcriptional repressor activity
  GO:0019901                     3.2 × 10^−5^     0.0072                15,767         57   169      6    protein kinase binding
  GO:0010843                     4.9 × 10^−5^     0.0112                15,767         57   111      5    promoter binding
  GO:0044212                     5.8 × 10^−5^     0.0132                15,767         57   115      5    DNA regulatory region binding

3. Experimental Section {#sec3-ijms-17-00216}
=======================

3.1. Overview of the Traumatic Brain Injury (TBI) Network Biomarkers Identification Process {#sec3dot1-ijms-17-00216}
-------------------------------------------------------------------------------------------

We used a theoretical framework to identify the evolution of TBI network biomarkers at four time points representing four important stages after the occurrence of a TBI. We have successfully used a similar theoretical framework to identify the network biomarkers of various cancers and stroke \[[@B31-ijms-17-00216],[@B32-ijms-17-00216],[@B33-ijms-17-00216]\]. We therefore highlight only the key points of this framework in this section, and describe the process in detail in the supplementary information ([Supplementary Material S0](#app1-ijms-17-00216){ref-type="app"}). The flowchart in [Figure 7](#ijms-17-00216-f007){ref-type="fig"} illustrates how we identified the network biomarkers of TBI at four time points. We combined two kinds of data sets to develop our model: (i) microarray data from both TBI and normal samples from the Gene Expression Omnibus (GEO) database, where TBI samples are divided into four groups according to the time post-injury (4, 8, 24, and 72 h); and (ii) a protein--protein interaction database, which was necessary to construct four candidate PPINs for TBI.

![The method by which we constructed the network markers for four time points with respect to TBI and investigated the underlying molecular mechanisms of TBI. BioGRID: Biological General Repository for Interaction Database.](ijms-17-00216-g007){#ijms-17-00216-f007}

Using several mathematical models, we constructed four TBI PPINs (TPPINs) and a normal PPIN (NPPIN). We also constructed four Differential PPINs (DPPINs) and calculated the TBI relevance value (TRV) for each protein in the DPPINs ([Supplementary Material S0](#app1-ijms-17-00216){ref-type="app"}).

3.2. Data Selection and Pre-Processing {#sec3dot2-ijms-17-00216}
--------------------------------------

To identify the regulatory mechanisms of brain trauma, we obtained microarray datasets from gene expression profiling of brain injury samples (4, 8, 24, and 72 h after surgery) and brain sham samples (4, 8, 24, and 72 h after sham surgery) in mice from the NCBI GEO \[[@B34-ijms-17-00216]\]. We chose GSE2392 \[[@B35-ijms-17-00216]\] and its corresponding platform, GPL81, as our research object ([Table 1](#ijms-17-00216-t001){ref-type="table"}). We collected expression profiling data for mice from the Gene Expression Omnibus (GEO), accession number GSE2392, and normalized it using quantile normalization. For each of the four time points, there were three TBI samples and two control samples, making a total of 20 samples.

The PPI dataset for *Mice* was downloaded from the public Biological General Repository for Interaction Database (BioGRID) \[[@B36-ijms-17-00216]\]. We excluded false-positive PPIs from the TBI PPINs using BioGRID and compared the resulting PPINs to identify network biomarkers ([Supplementary Material S0](#app1-ijms-17-00216){ref-type="app"}).

3.3. Selection of the Differential Protein Groups and Identification of PPINs {#sec3dot3-ijms-17-00216}
-----------------------------------------------------------------------------

We combined the gene expression profiles with the PPI database to construct the corresponding TPPINs and NPPIN. First, we identified a differential protein group containing proteins with differential expression. Protein expression profiles are not yet readily available, so we assumed that gene expression profiles are correlated with protein expression profiles. We used a one-way analysis of variance (ANOVA) or the fold change (FC) method to analyze the expression of each protein and select the proteins that were differentially expressed in cells. These methods were capable of identifying the critical proteins differentially expressed in TBI and normal samples. We eliminated proteins with no PPI information from the differential protein group. Proteins that were not already in the differential protein group were included if their PPI information indicated that they had a close relationship with a protein (number of edges \> 5) in the group. Thus, the differential protein group included the critical differential expression proteins and other closely related proteins.

We combined the critical differential protein group and PPI information to construct candidate PPINs by linking proteins that interacted with each other. In other words, proteins for which we had PPI information via the differential protein group were linked using our mathematical model to form the candidate TPPINs and NPPINs.

The candidate TPPINs and NPPINs included all possible PPIs under various biological conditions. It was then necessary to confirm them using microarray expression data and identify the proper PPIs according to the TBI processes. We used both the PPI model selection method and a model order detection strategy to exclude the false-positive PPIs. We could then express the relationship to the PPI of the *i*-th target protein in the candidate TPPINs and NPPINs with the following formula: $$x_{i}(n) = {\sum\limits_{j = 1}^{M_{i}}\alpha_{ij}}x_{j}(n) + \omega_{i}(n)$$where *x~i~*(*n*) is the expression levels of target protein *i* for sample *n*; *x~j~*(*n*) is the expression level of the *j*-th protein interacting with target protein *i* for sample *n*; α*~ij~* is the association ability between target protein *i* and its *j*-th interactive protein; *M~i~* is the number of proteins interacting with target protein *i*; and ω*~i~*(*n*) is stochastic noise due to other factors or model uncertainty. For the definitions of the terms, please refer to [Supplementary Material S1](#app1-ijms-17-00216){ref-type="app"}.

We then used the least squares parameter estimation method \[[@B37-ijms-17-00216]\] to determine the parameter of association strength in Equation (1) from the TBI microarray data as follows ([Supplementary Material S1](#app1-ijms-17-00216){ref-type="app"}): $$x_{i}(n) = {\sum\limits_{j = 1}^{M_{i}}{\hat{\alpha}}_{ij}}x_{j}(n),i = 1,2, \cdot \cdot \cdot ,M$$where ${\hat{\alpha}}_{ij}$ is solved using TBI microarray data and the least squares parameter estimation method.

Finally, we use AIC (Akaike information criterion) \[[@B37-ijms-17-00216]\] with a Student's *t*-test \[[@B38-ijms-17-00216]\] for model order determination and to determine the critical protein association strengths ${\hat{\alpha}}_{ij}$ ([Supplementary Material S2](#app1-ijms-17-00216){ref-type="app"}).

3.4. Determination of Proteins with Top TBI Relevance Value (TRV)and Their Corresponding Network Structures {#sec3dot4-ijms-17-00216}
-----------------------------------------------------------------------------------------------------------

The significant remaining PPIs after pruning the false-positives are expressed by the following: $$x_{i}(n) = {\sum\limits_{j = 1}^{{M_{i}}^{\prime}}{\hat{\alpha}}_{ij}}x_{j}(n) + w_{i}^{\prime}(n),i = 1,2, \cdot \cdot \cdot ,M$$where *M~i~*′ ≤ *M~i~* is the total number of significant PPIs remaining in the refined PPINs for target protein *i*. The final refined PPIN is as follows: $$X(n) = AX(n) + w(n)$$ $$X(n) = \begin{bmatrix}
{x_{1}(n)} \\
{x_{2}(n)} \\
 \vdots \\
{x_{M}(n)} \\
\end{bmatrix},A = \begin{bmatrix}
{\hat{\alpha}}_{11} & \cdots & {\hat{\alpha}}_{1M} \\
 \vdots & \ddots & \vdots \\
{\hat{\alpha}}_{M1} & \cdots & {\hat{\alpha}}_{MM} \\
\end{bmatrix},w(n) = \begin{bmatrix}
{w_{1}^{\prime}(n)} \\
{w_{1}^{\prime}(n)} \\
 \vdots \\
{w_{M}^{\prime}(n)} \\
\end{bmatrix}$$

The interaction matrix *A* of refined PPINs (*i.e.*, after pruning, as described by Equation (4) were constructed as follows: $$A_{T}^{K} = \begin{bmatrix}
{\hat{\alpha}}_{11,T}^{k} & \cdots & {\hat{\alpha}}_{1M,T}^{k} \\
 \vdots & \ddots & \vdots \\
{\hat{\alpha}}_{M1,T}^{k} & \cdots & {\hat{\alpha}}_{MM,T}^{k} \\
\end{bmatrix}A_{N} = \begin{bmatrix}
{\hat{\alpha}}_{11,N} & \cdots & {\hat{\alpha}}_{1M,N} \\
 \vdots & \ddots & \vdots \\
{\hat{\alpha}}_{M1,N} & \cdots & {\hat{\alpha}}_{MM,N} \\
\end{bmatrix}$$where *k* is time post-injury, $A_{T}^{K}$ and *A~N~* are the interaction strength matrices of the refined TPPINs and NPPIN for 4, 8, 24, and 72 h post-injury, respectively, and *M* is the total number of interaction proteins in the refined TPPINs and NPPIN after pruning. Thus, the protein interaction model can be expressed as follows: $$\begin{array}{l}
{x_{T}^{K}(n) = A_{T}^{k}x_{T}(n)} \\
{x_{N}(n) = A_{N}x_{N}(n)} \\
\end{array}$$where *k* is time post-injury and $x_{T}^{k}(n) = {\lbrack x_{1T}^{k}\ x_{2T}^{k}\ \cdots x_{MT}^{k}\rbrack}^{T}$ and $x_{N}(n) = {\lbrack x_{1N}\ x_{2N}\ \cdots x_{MN}\rbrack}^{T}$ are vectors of protein expression values. The difference matrix *D^k^* we used to interpret the differences in behavior between two networks is defined as follows: $$D^{k} = \begin{bmatrix}
d_{11}^{k} & \cdots & d_{1M}^{k} \\
 \vdots & \ddots & \vdots \\
d_{M1}^{k} & \cdots & d_{MM}^{k} \\
\end{bmatrix} = \begin{bmatrix}
{{\hat{\alpha}}_{11,T}^{k} - {\hat{\alpha}}_{11,N}} & \cdots & {{\hat{\alpha}}_{1M,T}^{k} - {\hat{\alpha}}_{1M,N}} \\
 \vdots & \ddots & \vdots \\
{{\hat{\alpha}}_{M1,T}^{k} - {\hat{\alpha}}_{M1,N}} & \cdots & {{\hat{\alpha}}_{MM,T}^{k} - {\hat{\alpha}}_{MM,N}} \\
\end{bmatrix}$$where *k* is time post-injury, $d_{ij}^{k}$ is the difference between the protein association capacity of the networks at different times post-injury, and matrix *D^k^* denotes the differences in network structures. To investigate TBI-related factors using matrix *D^k^*, we proposed a value we called the TBI relevance value (TRV) to quantify the significance of each protein in *D^k^* as follows \[[@B13-ijms-17-00216]\]: $$TRV^{k} = \begin{bmatrix}
{TRV_{1}^{k}} \\
 \vdots \\
{TRV_{i}^{k}} \\
 \vdots \\
{TRV_{M}^{k}} \\
\end{bmatrix}$$where $TRV_{i}^{k} = {\sum\limits_{j = 1}^{M}\left| d_{ij}^{k} \right|}$, and *k* is time post-injury ([Supplementary Material S0](#app1-ijms-17-00216){ref-type="app"}).

3.5. Pathway Analysis {#sec3dot5-ijms-17-00216}
---------------------

Our theory allowed us to construct the TPPINs and NPPINs and identify the network biomarkers with the highest TRVs. However, we also wanted to explore the biological significance of these network biomarkers; here, we used various software packages and on-line tools to do the functional pathway analysis. For example, we used KEGG \[[@B39-ijms-17-00216]\], the DAVID bioinformatics database \[[@B40-ijms-17-00216],[@B41-ijms-17-00216]\], and NOA \[[@B42-ijms-17-00216],[@B43-ijms-17-00216]\], which are the most commonly used free on-line tools, and MetaCore™ from Thomson Reuters, a powerful commercial software package that can do multiple functional and pathway analyses. A detailed description of the process we followed is given in [Supplementary Material S0](#app1-ijms-17-00216){ref-type="app"}.

3.6. Software and Databases Used in This Research {#sec3dot6-ijms-17-00216}
-------------------------------------------------

We conducted our analyses (AIC, student's t-test and least squares) using MATLAB's built-in functions. We also constructed the TPPINs, NPPIN, and TRB using MATLAB (The MathWorks, Inc., Natick, MA, USA). The version of the programs we used is not yet open-access. However, we suggest that readers refer to the old version of the theoretical framework and source code, which are available to the public \[[@B44-ijms-17-00216]\] ([Supplementary Material S3](#app1-ijms-17-00216){ref-type="app"}).

We used the MetaCore™ Enrichment Analysis (EA) Workflow tool (Thomson Reuters, New York, NY, USA) to analyze the experimental data in terms of their enrichment by the various ontologies in MetaCore™, including ontologies and GO ontologies: Pathway Maps, process networks, Diseases, metabolic networks, toxicity networks, and GO processes. The EA method involves mapping the selected experiments onto MetaCore™ ontologies in terms of their respective sets of genes or network objects, which are then sorted according to their *p-*values. We used the Compare Experiments Workflow tool (GeneGO, Inc., Encinitas, CA, USA) to compare the experimental data for the four time points post-TBI by analyzing their intersections in terms of their mapping onto the MetaCore™ ontologies. The Experiment Intersections method involves mapping the intersections of the selected experiments, which identifies the sets of genes common to all selected experiments, similar to some of them, or unique to a given experiment. We collated all of these sets of genes for further analysis and discussion. MetaCore™ is user-friendly, and various manuals and training materials can be download from public websites \[[@B45-ijms-17-00216],[@B46-ijms-17-00216]\]. However, due to copyright concerns, we have not copied the material here. We used Cytoscape Web \[[@B47-ijms-17-00216]\] to display the networks of critical biomarkers. Nodes and edges in the network represent genes and expression correlations between two genes, respectively. We used the ForceDirected approach as the default layout. Users can change the network display settings by altering parameter settings for nodes, edges, and layout. The GO database holds both the ontologies and the annotations in a single database and allows queries of the annotations and enrichment analyses using the ontologies \[[@B48-ijms-17-00216]\]. DAVID, KEGG, and NOA (A cytoscape plugin for network ontology analysis; Available online: <http://apps.cytoscape.org/apps/noa>) are easy-to-use web servers with user-friendly interfaces.

4. Conclusions {#sec4-ijms-17-00216}
==============

In conclusion, we used a publicly available high-throughput microarray to construct networks for four time points post-TBI. The powerful functional pathway analysis then extended the relevance of our research to a wider field. This work can help scientists and medical researchers reveal the underlying hidden mechanisms of TBI and improve biological models for TBI. However, the number of samples in this study was small. In future, we will include more data samples from humans and model organisms to develop a more precise and accurate model. In addition, we will integrate the GRN and PPI models to facilitate deeper interpretation of the regulatory and interaction mechanisms. This work can offer clues and information for developing novel biological models and strategies for target therapy to advance recovery processes.
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